BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 9247284)

  • 1. ELISA for complexes between urokinase-type plasminogen activator and its receptor in lung cancer tissue extracts.
    de Witte H; Pappot H; Brünner N; Grøndahl-Hansen J; Hoyer-Hansen G; Behrendt N; Guldhammer-Skov B; Sweep F; Benraad T; Danø K
    Int J Cancer; 1997 Jul; 72(3):416-23. PubMed ID: 9247284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies.
    Rønne E; Høyer-Hansen G; Brünner N; Pedersen H; Rank F; Osborne CK; Clark GM; Danø K; Grøndahl-Hansen J
    Breast Cancer Res Treat; 1995 Mar; 33(3):199-207. PubMed ID: 7749147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complexes between urokinase-type plasminogen activator and its receptor in blood as determined by enzyme-linked immunosorbent assay.
    De Witte H; Sweep F; Brünner N; Heuvel J; Beex L; Grebenschikov N; Benraad T
    Int J Cancer; 1998 Jul; 77(2):236-42. PubMed ID: 9650559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
    Pedersen H; Brünner N; Francis D; Osterlind K; Rønne E; Hansen HH; Danø K; Grøndahl-Hansen J
    Cancer Res; 1994 Sep; 54(17):4671-5. PubMed ID: 8062262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New ELISA for quantitation of human urokinase receptor (CD87) in cancer.
    Kotzsch M; Luther T; Harbeck N; Ockert D; Lutz V; Noack F; Grossmann D; Albrecht S; Kramer MD; Lossnitzer A; Grosser M; Schmitt M; Magdolen V
    Int J Oncol; 2000 Oct; 17(4):827-34. PubMed ID: 10995898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors.
    Solberg H; Rømer J; Brünner N; Holm A; Sidenius N; Danø K; Høyer-Hansen G
    Int J Cancer; 1994 Sep; 58(6):877-81. PubMed ID: 7927882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
    Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
    Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA.
    Pedersen AN; Høyer-Hansen G; Brünner N; Clark GM; Larsen B; Poulsen HS; Danø K; Stephens RW
    J Immunol Methods; 1997 Apr; 203(1):55-65. PubMed ID: 9134030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urokinase receptor variants in tissue and body fluids.
    Høyer-Hansen G; Lund IK
    Adv Clin Chem; 2007; 44():65-102. PubMed ID: 17682340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
    Mahanivong C; Yu J; Huang S
    Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding.
    Quax PH; Grimbergen JM; Lansink M; Bakker AH; Blatter MC; Belin D; van Hinsbergh VW; Verheijen JH
    Arterioscler Thromb Vasc Biol; 1998 May; 18(5):693-701. PubMed ID: 9598826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.
    Fuessel S; Erdmann K; Taubert H; Lohse-Fischer A; Zastrow S; Meinhardt M; Bluemke K; Hofbauer L; Fornara P; Wullich B; Baretton G; Magdolen V; Wirth MP; Kotzsch M
    BMC Cancer; 2014 Dec; 14():974. PubMed ID: 25519168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor.
    Olson D; Pöllänen J; Høyer-Hansen G; Rønne E; Sakaguchi K; Wun TC; Appella E; Danø K; Blasi F
    J Biol Chem; 1992 May; 267(13):9129-33. PubMed ID: 1315748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies.
    Carriero MV; Franco P; Del Vecchio S; Massa O; Botti G; D'Aiuto G; Stoppelli MP; Salvatore M
    Cancer Res; 1994 Oct; 54(20):5445-54. PubMed ID: 7923178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
    Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
    Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
    Abe J; Urano T; Konno H; Erhan Y; Tanaka T; Nishino N; Takada A; Nakamura S
    Cancer; 1999 Dec; 86(12):2602-11. PubMed ID: 10594855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
    Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
    Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levels of plasminogen activator inhibitor type 1 and urokinase plasminogen activator receptor in non-small cell lung cancer as measured by quantitative ELISA and semiquantitative immunohistochemistry.
    Pappot H; Skov BG; Pyke C; Grøndahl-Hansen J
    Lung Cancer; 1997 Jul; 17(2-3):197-209. PubMed ID: 9237155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme-linked immunosorbent assay of urokinase-type plasminogen activator (uPA) in cytosolic extracts of human breast cancer tissue.
    Rosenquist C; Thorpe SM; Danø K; Grøndahl-Hansen J
    Breast Cancer Res Treat; 1993 Dec; 28(3):223-9. PubMed ID: 8018952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.